Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

522 Postmarket Surveillance Studies Database
  • Print
  • Share
  • E-mail
-
The FDA has the authority to require device manufacturers to perform postmarket surveillance under Section 522 of the Food, Drugs and Cosmetics (FD&C) Act, when questions are identified for devices that meet the statutory criteria. This database contains information about 522 Postmarket Surveillance Studies that have been required. This database allows you to search information about the postmarket surveillance requirements by manufacturer or device.

Learn more...

            
  To search for Manufacturer beginning with a specific letter, select that letter
 
 A 
 B 
 C 
 D 
 E 
 F 
 G 
 H 
 I 
 J 
 L 
 M 
 N 
 O 
 P 
 R 
 S 
 T 
 U 
 V 
 W 
 X 
 Z 
 
 
   

Explant Analysis Study Plan


 
Suggest Enhancement / Report Issue | export reports to excelExport to Excel
General
Study Status Progress Adequate
522 Number / Requirement Number PS110002 / PSS006
Date Original Plan Accepted 02/04/2011
Date Current Plan Accepted 03/16/2016
Study Name Explant Analysis Study Plan
Device Name Tmj fossa-eminence/condylar prosthesis system
Root Document Number P000023  P000035 
General Study Protocol Parameters
Study Design Prospective Cohort Study
Data Source New Data Collection
Comparison Group No Control
Analysis Type Descriptive
Study Population Adult: >21
Detailed Study Protocol Parameters
Study Objectives This protocol will be applied to all explanted devices that are returned to Nexus CMF for four years from implementation of this protocol, whether or not the patient has been included in the prospective study.
Study Population All explanted devices that are returned to Nexus CMF for implantation of either a TMJ Fossa- Eminence and Condylar Prosthesis System or a TMJ Fossa- Eminence Prosthesis System.
Sample Size All explanted devices that are returned from the 278 subjects subjects for the Total Joint System and 278 subjects for the Partial Joint System.
Key Study Endpoints The study endpoints will include:
• Summary of clinical information.
• Summary of the dimensional analysis.
• Summary of the visual inspection including overall photographs along with photographs of areas of damage and/or wear.
• Summary of the profilometry measurements.
• Summary of scanning electron microscopy (SEM) and electron dispersion x-ray spectophotometry (EDS) analyses.
• Wear measurements.
• Summary of tissue analysis (if performed).
• Determination as to the cause of failure of the device
(if possible based on available information).
Follow-up Visits and Length of Follow-up 4 years


Explant Analysis Study Plan Reporting Schedule

Reporting Schedule
Report
Date Due
FDA Receipt
Date
Applicant's Reporting Status
6 month report 09/14/2016 09/16/2016 Overdue/Received
1 year report 03/16/2017 03/20/2017 Overdue/Received
18 month report 09/14/2017 02/01/2019 Overdue/Received
2 year report 03/16/2018   Overdue
3 year report 03/16/2019   Overdue
4 year report 03/15/2020   Overdue
5 year report 03/15/2021   Overdue
6 year report 03/15/2022   Overdue
7 year report 03/15/2023   Overdue
8 year report 03/15/2024   Overdue


Contact Us

Mandated Studies Program
Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993-0002
Email: MandatedStudiesPrograms@fda.hhs.gov

Additional Resources
-
-